Business Context and Reporting Period
Company: Teva Pharmaceutical Industries Ltd.
Filing Type: Form 20-F (Annual Report)
Period Ended: December 31, 2004
Business Overview: Teva is a global pharmaceutical company and one of the world's largest generic drug manufacturers, with a leading position in the U.S. generic market. The company operates two primary segments: Pharmaceuticals (generic and proprietary products, including the leading MS drug Copaxone) and Active Pharmaceutical Ingredients (API). In 2004, Teva completed its largest acquisition to date, purchasing Sicor Inc. for approximately $3.46 billion, significantly expanding its injectable and biogenerics capabilities.
Key Financial Metrics
| Metric (USD Millions) | 2004 | 2003 |
|---|---|---|
| Net Sales | 4,798.9 | 3,276.4 |
| Gross Profit | 2,239.3 | 1,518.9 |
| Operating Income | 577.8 | 877.4 |
| Net Income (GAAP) | 331.8 | 691.0 |
| Net Income (Normalized) | 964.6 | 617.8 |
| Diluted EPS (GAAP) | $0.50 | $1.16 |
| Diluted EPS (Normalized) | $1.42 | $1.04 |
| Cash Flow from Operations | 1,248.8 | 626.6 |
| Total Assets | 9,632.0 | 5,915.9 |
| Total Debt (Short + Long Term) | 2,288.8 | 1,459.6 |
| Shareholders' Equity | 5,388.9 | 3,289.4 |
Note: Normalized figures exclude one-time acquisition charges and litigation settlement gains to reflect underlying operational trends.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 46.5% to $4.8 billion, driven by the consolidation of Sicor Inc. (acquired Jan 2004), new generic product launches (e.g., Neurontin, OxyContin), and strong growth in the proprietary product Copaxone.
- Profitability Impact: Reported GAAP net income decreased 52% to $332 million due to a $596.6 million charge for in-process R&D related to the Sicor acquisition and a $30 million impairment of product rights. Conversely, normalized net income increased 56% to $965 million.
- Balance Sheet Expansion: Total assets grew 63% to $9.6 billion, primarily due to the acquisition of Sicor, which added significant goodwill ($1.8 billion) and intangible assets. Total debt increased to fund the acquisition, though the company maintained strong liquidity with $784 million in cash and cash equivalents.
- Margin Trends: Gross profit margin improved to 46.7% (from 46.4%), while operating margin (normalized) rose to 25.1% (from 24.0%).
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management views the Sicor acquisition as accretive and a strategic move to strengthen the injectables and API businesses. The company expects continued growth fueled by a robust U.S. generic pipeline (140 pending ANDAs) and the expansion of Copaxone sales, which reached a record quarterly market share of 32.6% in the U.S. in Q4 2004. Teva anticipates an effective tax rate of approximately 22% for 2005.
Key Risks & Contingencies:
- Patent Litigation: Teva faces significant patent challenges regarding generic versions of Neurontin, OxyContin, and Prilosec. While Teva has secured favorable rulings in some cases (e.g., OxyContin patents held unenforceable), adverse outcomes could result in damages or injunctions.
- Regulatory Environment: Changes in FDA policies regarding market exclusivity (Hatch-Waxman Act) and pricing regulations in Europe and Israel pose risks to revenue projections.
- Competition: Intense price competition in the generic market and the potential for "authorized generics" from brand-name companies could erode margins.
- Geopolitical: Operations in Israel are subject to risks related to terrorism and regional hostilities.
Investor Verification Checklist
- Normalized vs. GAAP Earnings: Verify the reconciliation of the $633 million one-time charge related to Sicor's in-process R&D to understand the true operational performance.
- Patent Litigation Status: Monitor the status of pending appeals regarding Neurontin (Pfizer) and OxyContin (Purdue) litigation, as these represent significant potential liabilities.
- Integration of Sicor: Assess the progress of integrating Sicor's injectable and API operations and the realization of anticipated synergies.
- Copaxone Market Share: Track Copaxone's market share against competitors (Avonex, Betaseron, Rebif) and the impact of the new competitor Tysabri (which was suspended in early 2005).
- Convertible Debt: Review the terms of the $1.1 billion in convertible debentures issued in 2004, specifically the contingent conversion features that could impact future dilution.